Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.
Counago F, Luna J, Guerrero LL, Vaquero B, Guillen-Sacoto MC, Gonzalez-Merino T, et al. Management of oligometastatic non-small cell lung cancer patients: current controversies and future directions. World J Clin Oncol. 2019;10(10):318–39.
Alexander M, Lin E, Cheng H. Leptomeningeal metastases in non-small cell lung cancer: optimal systemic management in NSCLC with and without driver mutations. Curr Treat Options Oncol. 2020;21(9):72.
Zhang M, Ma W, Liu H, Jiang Y, Qin L, Li W, et al. Osimertinib improves overall survival in patients with leptomeningeal metastases associated with egfr-mutated non-small-cell lung cancer regardless of cerebrospinal fluid T790M mutational status. Evid Based Complement Altern Med eCAM. 2021;2021:6968194.
Niu H, Zhou J, Maan H, Markman M, Niu J. Treatment of leptomeningeal metastases in a patient with non-small cell lung cancer harboring EGFR T790M mutation. Case Rep Oncol. 2017;10(3):840–5.
Hendriks LEL, Bootsma G, Mourlanette J, Henon C, Mezquita L, Ferrara R, et al. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. Eur J Cancer. 2019;116:182–9.
How J, Mann J, Laczniak AN, Baggstrom MQ. Pulsatile erlotinib in EGFR-positive non-small-cell lung cancer patients with leptomeningeal and brain metastases: review of the literature. Clin Lung Cancer. 2017;18(4):354–63.
Wang Y, Liu S, Wei X, Yan B, Li J, Su Z, et al. Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report. Onco Targets Ther. 2018;11:4733–8.
Carmona-Bayonas A, Gomez D, Martinez de Castro E, Perez Segura P, Munoz Langa J, Jimenez-Fonseca P, et al. A snapshot of cancer-associated thromboembolic disease in 2018–2019: first data from the TESEO prospective registry. Eur J Internal Med. 2020;78:41–9.
Shimizu Y, Okada K, Adachi J, Abe Y, Narumi R, Uchibori K, et al. GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer. NPJ Precision Oncol. 2022;6(1):16.
Xin XL, Wang GD, Han R, Jiang Y, Liu C, Liu LS, et al. Mechanism underlying the effect of Liujunzi decoction on advanced-stage non-small cell lung cancer in patients after first-line chemotherapy. J Tradit Chin Med Chung i tsa chih ying wen pan. 2022;42(1):108–15.
Vismara M, Reduzzi C, Silvestri M, Murianni F, Lo Russo G, Fortunato O, et al. Single-cell phenotypic and molecular characterization of circulating tumor cells isolated from cryopreserved peripheral blood mononuclear cells of patients with lung cancer and sarcoma. Clin Chem. 2022;68:691–701.
Natarajan SR, Ponnusamy L, Manoharan R. MARK2/4 promotes Warburg effect and cell growth in non-small cell lung carcinoma through the AMPKalpha1/mTOR/HIF-1alpha signaling pathway. Biochim Biophys Acta. 2022;1869(7): 119242.
Zheng Y, Tang L, Liu Z. Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer. BMC Cancer. 2021;21(1):1322.
Zhu W, Shi L, Gong Y, Zhuo L, Wang S, Chen S, et al. Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non-small cell lung cancer (NSCLC) via the PI3K/AKT pathway. Thorac Cancer. 2022;13:1027–39.
Dong Y, Tian J, Yan B, Lv K, Li J, Fu D. Liver-metastasis-related genes are potential biomarkers for predicting the clinical outcomes of patients with pancreatic adenocarcinoma. Pathol Oncol Res POR. 2021;27:1609822.
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7): e47.
Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7.
Saboundji K, Auliac JB, Perol M, Francois G, Janicot H, Marcq M, et al. Efficacy of osimertinib in EGFR-mutated non-small cell lung cancer with leptomeningeal metastases pretreated with EGFR-tyrosine kinase inhibitors. Target Oncol. 2018;13(4):501–7.
Li K, Guo S, Tong S, Sun Q, Jin S, Qi B, et al. Identification of keratinocyte differentiation-involved genes for metastatic melanoma by gene expression profiles. Comput Math Methods Med. 2021;2021:9652768.
Sigin VO, Kalinkin AI, Kuznetsova EB, Simonova OA, Chesnokova GG, Litviakov NV, et al. DNA methylation markers panel can improve prediction of response to neoadjuvant chemotherapy in luminal B breast cancer. Sci Rep. 2020;10(1):9239.
Qiao J, Cui SJ, Xu LL, Chen SJ, Yao J, Jiang YH, et al. Filamin C, a dysregulated protein in cancer revealed by label-free quantitative proteomic analyses of human gastric cancer cells. Oncotarget. 2015;6(2):1171–89.
Wu M, Michaud EJ, Johnson DK. Cloning, functional study and comparative mapping of Luzp2 to mouse chromosome 7 and human chromosome 11p13-11p14. Mamm Genome Off J Int Mamm Genome Soc. 2003;14(5):323–34.
Stepanov V, Vagaitseva K, Bocharova A, Marusin A, Markova V, Minaycheva L, et al. Analysis of association of genetic markers in the LUZP2 and FBXO40 genes with the normal variability in cognitive performance in the elderly. Int J Alzheimer’s Disease. 2018;2018:2686045.
Zhao J, Zhao Y, Wang L, Zhang J, Karnes RJ, Kohli M, et al. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. Oncotarget. 2016;7(25):38551–65.
Wang F, Hu YL, Feng Y, Guo YB, Liu YF, Mao QS, et al. High-level expression of PRSS3 correlates with metastasis and poor prognosis in patients with gastric cancer. J Surg Oncol. 2019;119(8):1108–21.
Raczkowski HL, Xu LS, Wang WC, DeKoter RP. The E26 Transformation-Specific-family transcription factor Spi-C is dynamically regulated by external signals in B cells. bioRxiv. 2021:2021.08.25.457658.
Khanna P, Lee JS, Sereemaspun A, Lee H, Baeg GH. GRAMD1B regulates cell migration in breast cancer cells through JAK/STAT and Akt signaling. Sci Rep. 2018;8(1):9511.
Khanna P, Chua PJ, Wong BSE, Yin C, Thike AA, Wan WK, et al. GRAM domain-containing protein 1B (GRAMD1B), a novel component of the JAK/STAT signaling pathway, functions in gastric carcinogenesis. Oncotarget. 2017;8(70):115370–83.
Rana M, Kansal R, Chaib M, Teng B, Morrrison M, Hayes DN, et al. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-beta receptor plus dual checkpoint inhibition maintains antitumor immune cells. Mol Carcinog. 2022;61:549–57.
Wang Y, Chen R, Wa Y, Ding S, Yang Y, Liao J, et al. Tumor immune microenvironment and immunotherapy in brain metastasis from non-small cell lung cancer. Front Immunol. 2022;13: 829451.
Jiang WY, Lei QY, Liu SS, Yang L, Yang B, Zhang Y. The effect of HOXC10 gene on biological behaviors of glioma cells and mechanism in tumor microenvironment. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2022;44(3):228–37.
Kim CG, Kim G, Kim KH, Park S, Shin S, Yeo D, et al. Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer. J Immunother Cancer. 2021;9(12):e002780.
Guo Q, Xiao XY, Wu CY, Li D, Chen JL, Ding XC, et al. Clinical roles of risk model based on differentially expressed genes in mesenchymal stem cells in prognosis and immunity of non-small cell lung cancer. Front Genet. 2022;13: 823075.
Lee H, Choi H. Investigating the clinico-molecular and immunological evolution of lung adenocarcinoma using pseudotime analysis. Front Oncol. 2022;12: 828505.
Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu Rev Pathol. 2018;13:395–412.
Siersbaek R, Scabia V, Nagarajan S, Chernukhin I, Papachristou EK, Broome R, et al. IL6/STAT3 signaling hijacks estrogen receptor alpha enhancers to drive breast cancer metastasis. Cancer Cell. 2020;38(3):412–23 e9.